Cutaneous manifestations of Taxol therapy

Invest New Drugs. 1995;13(3):261-3. doi: 10.1007/BF00873811.


Taxol is a novel chemotherapeutic agent that has produced substantial responses in early clinical studies [1]. Taxol has excellent activity in a number of malignancies based on recently completed clinical trials, including a 30% response rate in platinum-refractory ovarian cancer patients [2-5]. We are currently conducting trials of dose-intense taxol with granulocyte colony stimulating factor (G-CSF) support in relapsed or refractory ovarian cancer patients. Such dose intensification produces a major response rate in 50% of patients with this disease [6]. Taxol was supplied in 5 ml ampules (6 mg/ml) in polyethoxylated castor oil (Cremophor EL) 50% and dehydrated alcohol and the dose was diluted in either 0.9% sodium chloride or 5% dextrose at concentrations of 0.6 to 1.2 mg/ml. We have noted 3 patients with previously unreported cutaneous manifestations which we believe are taxol related and also report our overall complication rate with the administration of taxol by peripheral intravenous lines.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Dermatitis, Contact / etiology*
  • Drug Therapy, Combination
  • Extravasation of Diagnostic and Therapeutic Materials / complications
  • Female
  • Granulocyte Colony-Stimulating Factor / drug effects
  • Humans
  • Middle Aged
  • Nail Diseases / chemically induced*
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Paclitaxel / adverse effects*
  • Paclitaxel / therapeutic use


  • Antineoplastic Agents, Phytogenic
  • Granulocyte Colony-Stimulating Factor
  • Paclitaxel